Dual Metformin + GLP-1 Drug Therapy Cuts Cancer Incidence 39% and Mortality 67% in Diabetics | Research

The takeaway

Dual metformin + GLP-1 RA therapy was associated with 39% lower adiposity-related cancer incidence and 67% lower all-cause mortality compared to DPP-4i over 5 years in T2D patients.

67% less mortality
Combining metformin with GLP-1 drugs was associated with two-thirds lower death rate compared to DPP-4 inhibitors over 5 years

What the researchers found

Cancer incidence HR: metformin 0.96; GLP-1 RA 0.86; dual 0.61. All-cause mortality HR: metformin 0.78; GLP-1 RA 0.61; dual 0.33. Dual therapy effects strongest in younger, male, obese patients.

Why it matters

A 39% cancer reduction and 67% mortality reduction from combining two commonly used drugs could save thousands of lives annually.

How the study worked

Retrospective TriNetX cohort analysis, T2D patients compared to DPP-4i reference, propensity-matched 1:1, 5-year follow-up for adiposity-related cancer incidence and all-cause mortality.

What this study cannot tell us

Observational. Cannot prove causation. May reflect healthier patient behavior in dual therapy group. Specific cancer types not individually powered.

How to read the evidence

Large propensity-matched observational study with striking effect sizes. Needs prospective validation.

When this study was published

Published in 2025.

The bigger picture

This suggests metformin and GLP-1 drugs fight cancer through complementary mechanisms, and their combination may represent the most effective pharmacological cancer prevention strategy in diabetics.

Questions still open

What mechanisms explain the synergistic cancer reduction?
Should dual therapy be standard for cancer prevention in diabetic patients?
Would adding SGLT2i create even greater cancer protection?

Common questions

Can diabetes drugs prevent cancer?

This study found combining metformin with GLP-1 drugs reduced obesity-related cancer by 39% and death by 67% in diabetic patients. Each drug alone helped, but the combination was dramatically better.

Why does the combination work so well?

Metformin and GLP-1 drugs likely fight cancer through different mechanisms (AMPK activation, anti-inflammation, weight loss, metabolic improvement). Together, they address multiple cancer-promoting pathways simultaneously.

Read the original research

Synergistic associations of metformin and GLP-1 receptor agonist use with adiposity-related cancer incidence in people living with type 2 diabetes.

Diabetes, obesity & metabolism, 28(2), 946-959

View on PubMed ↗Publisher’s paper ↗

Citation

Henney, Alex E; Heague, Megan; Riley, David R; Hydes, Theresa J; Anson, Matthew; Alam, Uazman; Cuthbertson, Daniel J. (2026). Synergistic associations of metformin and GLP-1 receptor agonist use with adiposity-related cancer incidence in people living with type 2 diabetes.. Diabetes, obesity & metabolism, 28(2), 946-959. https://doi.org/10.1111/dom.70267